research use only

Methyl methanesulfonate DNA alkylator chemical

Name: Methyl methanesulfonate
Brand: Selleck Chemicals
SKU: E0609
Rating: 5 (5 reviews)

Cat.No.E0609

Methyl methanesulfonate (MMS), a DNA alkylating agent, modifies both guanine (to 7-methylguanine) and adenine (to 3-methlyladenine) to cause base mispairing and replication blocks, respectively.

Chemical Structure

Molecular Weight: 110.13

Jump to

Quality Control

Batch: Purity: 98.49%

98.49

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase
Other DNA alkylator Inhibitors	Lomeguatrib Lobaplatin (D-19466) Tretazicar (CB1954) Treosulfan Semustine

Chemical Information, Storage & Stability

Molecular Weight	110.13	Formula	C₂H₆O₃S	Storage (From the date of receipt)	2 years -20°C liquid
CAS No.	66-27-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MMS			Smiles	CO[S](C)(=O)=O

Solubility

In vitro
Batch:

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.100mg/ml (9.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 22 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.275mg/ml (2.50mM)	Taking the 1 mL working solution as an example, add 50 μL of 5.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	DNA alkylator
In vitro	Methyl methanesulfonate(MMS) is used for DNA damaging agent to induce mutagenesis. The repair of MMS-induced heat-labile damage requires the base excision repair protein XRCC1, and is independent of Homologous recombination in both S.cerevisiae and mammalian cells.
In vivo	Methyl methanesulfonate(MMS) , as a genotoxic compound, has DNA damage potential in multiple organs such as the liver, kidneys and bone marrow in mice, confirmed by the in vivo comet assay.
References	[1] https://pubmed.ncbi.nlm.nih.gov/2195323/ [2] https://pubmed.ncbi.nlm.nih.gov/16009812/ [3] https://pubmed.ncbi.nlm.nih.gov/19043273/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05316220	Not yet recruiting	Ulcerative Colitis (UC)	AbbVie	September 15 2024	Phase 3
NCT05806255	Not yet recruiting	Palliative Care	William Osler Health System\|Humber River Hospital\|The Ottawa Hospital\|Bruyere Research Institute\|University of Ottawa\|Ottawa Hospital Research Institute\|University of Toronto\|Queen''s University\|McMaster University	July 1 2024	Not Applicable
NCT05703373	Not yet recruiting	Pregnancy Related	University of Pennsylvania	June 2024	Not Applicable
NCT06254950	Recruiting	Ulcerative Colitis	Takeda	March 29 2024	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):